Olanzapine. A pharmacoeconomic review of its use in schizophrenia (Q33761583)

29 July 2017

1 reference

title

Olanzapine. A pharmacoeconomic review of its use in schizophrenia (English)

1 reference

29 July 2017

1 reference

R H Foster

1

1 reference

29 July 2017

K L Goa

series ordinal

2

1 reference

29 July 2017

publication date

1 June 1999

1 reference

29 July 2017

1 reference

29 July 2017

volume

15

1 reference

29 July 2017

issue

6

1 reference

29 July 2017

page(s)

611-640

1 reference

The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations

29 July 2017

cites work

1 reference

12 December 2020

An economic evaluation of schizophrenia--1991.

1 reference

12 December 2020

Atypical antipsychotics for treatment of depression in schizophrenia and affective disorders. Collaborative Working Group on Clinical Trial Evaluations

1 reference

12 December 2020

Comments on article by Tran and associates, "Double-blind comparison of olanzapine versus risperidone in treatment of schizophrenia and other psychotic disorders"

1 reference

12 December 2020

Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol

1 reference

12 December 2020

Reliability, validity, and application of the medical outcomes study 36-item short-form health survey (SF-36) in schizophrenic patients treated with olanzapine versus haloperidol.

1 reference

12 December 2020

The costs of schizophrenia. Assessing the burden.

1 reference

12 December 2020

Neuroleptic withdrawal in schizophrenic patients. A review of the literature

1 reference

12 December 2020

Side effect profiles of new antipsychotic agents

1 reference

12 December 2020

Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia. Results from a randomised clinical trial

1 reference

12 December 2020

Why do schizophrenic patients refuse to take their drugs?

1 reference

12 December 2020

Methods for evaluation of the direct and indirect costs of long-term schizophrenia

1 reference

12 December 2020

Dosing the antipsychotic medication olanzapine

1 reference

12 December 2020

The cost of cognitive impairment in schizophrenia

1 reference

12 December 2020

The new epidemiology of schizophrenia

1 reference

12 December 2020

Management of treatment-resistant schizophrenia with olanzapine

1 reference

12 December 2020

Two-year outcome in first-episode schizophrenia: predictive value of symptoms for quality of life.

1 reference

12 December 2020

Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol

1 reference

12 December 2020

Some aspects of the cost of schizophrenia in France.

1 reference

12 December 2020

Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol

1 reference

12 December 2020

Measuring the costs of schizophrenia. Implications for the post-institutional era in the US.

1 reference

12 December 2020

Risperidone and olanzapine: optimal dosing for efficacy and tolerability in patients with schizophrenia

1 reference

12 December 2020

Comments on article by Tran and colleagues, "Double-blind comparison of olanzapine versus risperidone in treatment of schizophrenia and other psychotic disorders"

1 reference

12 December 2020

Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophrenia

1 reference

12 December 2020

Predictability of rehospitalisation over 5 years for schizophrenia, bipolar disorder and depression.

1 reference

12 December 2020

Translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations.

1 reference

12 December 2020

Effectiveness of combining atypical antipsychotics and psychosocial rehabilitation in a community mental health center setting.

1 reference

12 December 2020

Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses

1 reference

12 December 2020

Problems of using modelling in the economic evaluation of health care

1 reference

12 December 2020

Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial

1 reference

12 December 2020

Pharmacoeconomic evaluation of antipsychotic therapy for schizophrenia

1 reference

12 December 2020

A cost-effectiveness clinical decision analysis model for schizophrenia

1 reference

12 December 2020

Olanzapine. A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses

1 reference

12 December 2020

Building castles on sands or quicksands? The strengths and weaknesses of economic evaluation in pharmaceuticals

1 reference

12 December 2020

Health care expenditure on schizophrenia patients in Belgium

1 reference

12 December 2020

A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia.

1 reference

12 December 2020

Modeling the lifetime costs of treating schizophrenia in Australia

1 reference

12 December 2020

Olanzapine versus placebo and haloperidol: quality of life and efficacy results of the North American double-blind trial.

1 reference

12 December 2020

Excess mortality of schizophrenia. A meta-analysis

1 reference

12 December 2020

Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial.

1 reference

12 December 2020

Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.

1 reference

12 December 2020

Use of risperidone and olanzapine in outpatient clinics at six Veterans Affairs hospitals

1 reference

12 December 2020

Costs of schizophrenia in The Netherlands

1 reference

12 December 2020

Excess mortality of mental disorder

1 reference

12 December 2020

The Scottish first episode schizophrenia study. VIII. Five-year follow-up: clinical and psychosocial findings. The Scottish Schizophrenia Research Group

1 reference

12 December 2020

Formulary decisions and health economics.

1 reference

12 December 2020

A pharmacoeconomic model of outpatient antipsychotic therapy in "revolving door" schizophrenic patients

1 reference

12 December 2020

Practice guideline for the treatment of patients with schizophrenia. American Psychiatric Association

1 reference

12 December 2020

The cost of schizophrenia.

1 reference

12 December 2020

Cost Analysis of the Treatment of Schizophrenia in the UK

1 reference

12 December 2020

[Cost effectiveness analysis of olanzapine versus haloperidol in the treatment of schizophrenia++ in Spain]

1 reference

12 December 2020

Atypical antipsychotics in the managed care era.

1 reference

12 December 2020

Compliance with antipsychotic drug treatment: influence of side effects.

1 reference

12 December 2020

Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial

1 reference

12 December 2020

1 reference

12 December 2020

Quality of life in schizophrenia: insight and subjective response to neuroleptics.

1 reference

12 December 2020

[Occupational integration of schizophrenic patients under current treatment conditions]

1 reference

12 December 2020

Drug utilization patterns and outcomes associated with in-hospital treatment with risperidone or olanzapine.

1 reference

12 December 2020

Pharmacoeconomic Assessment of Olanzapine in the Treatment of Refractory Schizophrenia Based on a Pilot Clinical Study

1 reference

12 December 2020

The MOS 36-Item Short Form Health Survey: reliability, validity, and preliminary findings in schizophrenic outpatients.

1 reference

12 December 2020

Negative symptoms: diagnosis, treatment and prognosis.

1 reference

12 December 2020

Olanzapine versus haloperidol treatment in first-episode psychosis

1 reference

12 December 2020

Subjective quality of life in out-patients with schizophrenia: clinical and utilization correlates.

1 reference

12 December 2020

Economic outcomes and costs in the treatment of schizophrenia

1 reference

12 December 2020

Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: quality of life and clinical outcomes of a randomized clinical trial.

1 reference

12 December 2020

Financial cost of treating out-patients with schizophrenia in Nigeria.

1 reference

12 December 2020

Minimizing the non-extrapyramidal side-effects of antipsychotics

1 reference

12 December 2020

Assessment issues and the cost of schizophrenia

1 reference

12 December 2020

Olanzapine versus haloperidol in the treatment of schizoaffective disorder. Acute and long-term therapy.

1 reference

12 December 2020

Costs of schizophrenia

1 reference

12 December 2020

Treatment of schizophrenia: let's talk dollars and sense.

1 reference

12 December 2020

Economics and schizophrenia: the real cost.

1 reference

12 December 2020

Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia

1 reference

12 December 2020

The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome

1 reference

12 December 2020

Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial

1 reference

12 December 2020

Health economics and cost implications of anxiety and other mental disorders in the United States.

1 reference

12 December 2020

Olanzapine in treatment-refractory schizophrenia: results of an open-label study. The Spanish Group for the Study of Olanzapine in Treatment-Refractory Schizophrenia

1 reference

12 December 2020

Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia

1 reference

12 December 2020

Health care reform for Americans with severe mental illnesses: report of the National Advisory Mental Health Council

1 reference

12 December 2020

Cost of relapse in schizophrenia

1 reference

12 December 2020

The economic burden of mental illness

1 reference

12 December 2020

Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine

1 reference

12 December 2020

Measuring quality of life in patients with schizophrenia

1 reference

12 December 2020

Risperidone. A pharmacoeconomic review of its use in schizophrenia

1 reference

12 December 2020

Methods of pharmacoeconomic evaluation of psychopharmacologic therapies for patients with schizophrenia

1 reference

12 December 2020

Characteristics of very poor outcome schizophrenia

1 reference

12 December 2020

An open trial of olanzapine in patients with treatment-refractory psychoses.

1 reference

12 December 2020

Cost of illness studies for schizophrenia: components, benefits, results, and implications

1 reference

12 December 2020

10.2165/00019053-199915060-00008

Identifiers

DOI

1 reference

Dimensions Publication ID

29 July 2017

1017030075

0 references

Fatcat ID

release_zjbtfwsdfjh53asyqawxsd3h7m

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/zjbtfwsdfjh53asyqawxsd3h7m

24 November 2022

mapped directly with Wikidata item

1 reference